Vertex Pharmaceuticals (NASDAQ: VRTX)
Vertex Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Vertex Pharmaceuticals Company Info
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
News & Analysis
VanEck Biotech ETF (BBH): How to Buy
The Smartest Growth Stock to Buy With $500 Right Now
Vertex isn't your run-of-the-mill biotech stock.
Investing in Biotech Stocks in 2025
Top Biotech ETFs to Buy Now
Here are the five best biotech ETFs to invest in right now.
Investing in Gene-Editing Stocks
How to Invest in iShares Biotechnology ETF (IBB)
Biotech vs. Pharma: What's the Difference?
How to Invest in CRISPR Therapeutics Stock
Valuation
Podcast Episodes
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Earnings Transcripts
Vertex Pharmaceuticals (VRTX) Q4 2024 Earnings Call Transcript
VRTX earnings call for the period ending December 31, 2024.
Vertex Pharmaceuticals (VRTX) Q3 2024 Earnings Call Transcript
VRTX earnings call for the period ending September 30, 2024.
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
VRTX earnings call for the period ending June 30, 2024.
Vertex Pharmaceuticals (VRTX) Q1 2024 Earnings Call Transcript
VRTX earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.